Guillain-Barré Case Reported After Covid-19 Vaccination

Guillain-Barré Case Reported After Covid-19 Vaccination


Apr 9, 2021
Available evidence does not support causal inference
Clinical details of a participant in a Covid-19 vaccine trial who developed Guillain-Barré syndrome (GBS) after vaccination were published in
Two cases of GBS, one in the active and one in the placebo arm, were reported in the Ad26.COV2.S (Johnson & Johnson) Covid-19 vaccine trial data. “Our patient in the vaccine arm did not have any clinical features differentiating her from patients with typical GBS,” wrote Anthony Amato, MD, and co-authors, all of Brigham and Women’s Hospital, Boston.
“From the available evidence, it is not possible to draw causal inferences about the association of Covid-19 vaccination and the development of GBS,” they added.

Related Keywords

Boston , Massachusetts , United States , Oregon , Netherlands , Paul Smyth , Joep Killestein , Dennis Bourdette , Strongbridge Pharma , S Johnson Covid , Anthony Amato , Oregon Health Science University In Portland , Vrije University Amsterdam , Oregon Health , Science University , Contributing Writer , போஸ்டன் , மாசசூசெட்ஸ் , ஒன்றுபட்டது மாநிலங்களில் , ஓரிகந் , நெதர்லாந்து , பால் ஸ்மித் , அந்தோணி அமடோ , ஓரிகந் ஆரோக்கியம் அறிவியல் பல்கலைக்கழகம் இல் போர்டிலந்ட் , ஓரிகந் ஆரோக்கியம் , அறிவியல் பல்கலைக்கழகம் ,

© 2025 Vimarsana